Income statement
CHF
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 8M | 6M | 6M | 3M | 0 |
| Gross Profit | 6M | 4M | 5M | 3M | -14M |
| Operating Income | -19M | -111M | -52M | -34M | -9M |
| EBITDA | -17M | -108M | -49M | -33M | -19M |
| Net Income | -17M | -98M | -51M | -35M | -8M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.291
-13.13% today
1Y Change
-89.56%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
MindMaze Therapeutics Holding S.A. (RLFTF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.29 and down 89.6% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +39.5%, EPS growth of +83.6%, a dividend yield of 0.0%. What stands out right now is revenue +39.5%, EPS +83.6%, free cash flow +82.9% with operating margin 0.0% and ROIC 0.0%. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RLFTF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RLFTF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RLFTF Max Drawdown
-93.53%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RLFTF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$7.8M
+77.4% YoY
Free Cash Flow
-$18.3M
+63.1% YoY
Revenue Growth
+39.5%
EPS Growth
+83.6%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
CHF
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 8M | 6M | 6M | 3M | 0 |
| Gross Profit | 6M | 4M | 5M | 3M | -14M |
| Operating Income | -19M | -111M | -52M | -34M | -9M |
| EBITDA | -17M | -108M | -49M | -33M | -19M |
| Net Income | -17M | -98M | -51M | -35M | -8M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CHF
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 15M | 15M | 19M | 45M | 38M |
| Total Assets | 53M | 76M | 189M | 252M | 78M |
| Total Liabilities | 17M | 24M | 43M | 70M | 11M |
| Shareholder Equity | 37M | 52M | 145M | 182M | 67M |
| Total Debt | 2M | 3M | 3M | 3M | 891K |
| Net Debt | -13M | -12M | -16M | -42M | -37M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
18M
+48.9% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
18M
+63.1% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
0.0%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.